[
1. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.10.1200/JCO.2005.06.081
]Search in Google Scholar
[
2. Rozman A, Silar M, Kosnik M. Angiogenin and vascular endothelial growth factor expression in lungs of lung cancer patients. Radiol Oncol 2012; 46: 354-9.10.2478/v10019-012-0031-1
]Search in Google Scholar
[
3. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.10.1056/NEJM199101033240101
]Search in Google Scholar
[
4. Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, et al. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. Med Oncol 2009; 26: 480-90.10.1007/s12032-008-9157-9
]Search in Google Scholar
[
5. Liu Y, Tamimi RM, Collins LC, Schnitt SJ, Gilmore HL, Connolly JL, et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses’ Health Study. Breast Cancer Res Treat 2011; 129: 175-84.10.1007/s10549-011-1432-3
]Search in Google Scholar
[
6. Matos M, Zakotnik B, Grasic Kuhar C. Effectiveness of adjuvant transtuzmab in daily clinical practice. Radiol Oncol 2013; Ahead of print; doi:10.2478/ raon-2013-008. Available from: http://www.degruyter.com/view/j/raon.ahead-of-print/raon-2013-0081/raon-2013-0081.xml?format=INT
]Search in Google Scholar
[
7. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-30.
]Search in Google Scholar
[
8. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000; 19: 3460-9.10.1038/sj.onc.1203685
]Search in Google Scholar
[
9. Epstein M, Ayala R, Tchekmedyian N, Borgstrom P, Pegram M, Slamon D. HER-2/neu-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelialgrowthfactor(VEGF). [Abstract]. Breast Cancer Res Treat 2002; 76(Suppl 1): S143.
]Search in Google Scholar
[
10. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-80.10.1038/416279b
]Search in Google Scholar
[
11. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004; 10: 1706-16.10.1158/1078-0432.CCR-0951-3
]Search in Google Scholar
[
12. Linderholm B, Andersson J, Lindh B, Beckman L, Erlanson M, Edin K, et al. Overexpression of c-erbB-2 is related to a higherexpression of vascular endothelial growth factor (VEGF) and constitutes anindependent prognostic factor in primary node-positive breast cancer afteradjuvant systemic treatment. Eur J Cancer 2004; 40: 33-42.10.1016/S0959-8049(03)00673-7
]Search in Google Scholar
[
13. Pegram M, Yeon C, Ku N, Gaudreault J, Slamon DJ. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). [Abstract]. Breast Cancer Res Treat 2004; 88(Suppl 1): S124-5.
]Search in Google Scholar
[
14. Pegram M, Chan D, Dichmann R, Tar-Chin E, Yeon C, Duran L, et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line therapy of HER2 amplified breast cancer. Breast Cancer Res Treat 2006; 100(Suppl 1): S28-9.
]Search in Google Scholar
[
15. BETH Study: Treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastuzumab plus bevacizumab. Available at http://clinicaltrials.gov/ct2/show/NCT00625898?term=BETH&rank=1
]Search in Google Scholar
[
16. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779-86.10.1007/s00280-007-0664-818205003
]Search in Google Scholar
[
17. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-5.10.1200/JCO.2003.10.06612506171
]Search in Google Scholar
[
18. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-44.10.1200/JCO.2006.09.630517442997
]Search in Google Scholar
[
19. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013; 10: 1719-25.10.1200/JCO.2012.44.791223569311
]Search in Google Scholar
[
20. ECOG 1105: First-line chemotherapy and trastuzumab with or without bevacizumab in treating patients with metastatic breast cancer that overexpresses HER-2/NEU. Available at: http://clinicaltrials.gov/ct2/results?term=ECOG+1105&Search=Search
]Search in Google Scholar
[
21. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012; 366: 109-19.10.1056/NEJMoa1113216570520222149875
]Search in Google Scholar
[
22. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367: 1783-91. 10.1056/NEJMoa1209124512525023020162
]Search in Google Scholar